Massachusetts Prostate Cancer Coalition is a statewide non-profit organization devoted to providing information and education on prostate cancer for newly diagnosed individuals, survivors, men-at-risk, and their families as well as for health care professionals.
MPCC sponsors research on prostate cancer in collaboration with local hospitals and various health care providers and engages people across the Commonwealth in outreach to increase funding for prostate cancer education and research.
MPCC hosts events, funds local research, provides resources for patients and their families, and provides a platform for learning and discussing the issue of prostate cancer.
Support MPCC by becoming a member, making a donation or attending an event. More information can be found here.
Five Facts about Prostate Cancer
1PrevalenceProstate cancer is the most common (non-skin) cancer in American men.
2Prostate cancer effects 1 in 6 men.1 in 6 men will be diagnosed with prostate cancer during their lifetime. This year in Massachusetts another 4,820 new cases will be diagnosed.
3Second leading cause of cancer death in men.Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. In Massachusetts, 600 men will die from prostate cancer this year.
4Prostate cancer top risk factors.
African-American men are twice as likely to die of prostate cancer as white men. Asian-Americans and Hispanic/Latinos have lower rates of prostate cancer than non-Hispanic white men.
Almost 2 out of 3 prostate cancers are found in men over the age of 65.
5This year 29,720 men will die of prostate cancer.
Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.5 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today. How do we “live with prostate cancer”?
Statistics from The American Cancer Society 2013
We need your support! Become a Member or Donate to MPCC today.
New evidence lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis. The data are some of the first to demonstrate this dynamic in transgenic animal models, with promising implications for development of targeted therapies for prostate cancer and perhaps for other solid-tumor cancers. A team of researchers at Roswell.. read more →
An observational study from UCLA’s Jonsson Comprehensive Cancer comparing robotic-assisted surgery to traditional surgery for prostate cancer found that patients who had robotic surgery saw fewer instances of cancer cells remaining after surgery and less need of additional cancer treatments, than patients who had traditional surgery. Led by Dr. Jim Hu, Associate Professor and Henry.. read more →